Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on CareDx (NASDAQ:CDNA) and raises the price target from $16 to $26.
August 01, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on CareDx and raises the price target from $16 to $26.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100